ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.00
0.60
( 1.45% )
Updated: 14:30:37
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.00
Bid
40.60
Ask
41.00
Volume
557
41.40 Day's Range 42.20
0.00 52 Week Range 0.00
Previous Close
41.40
Open
41.80
Last Trade
5
@
42
Last Trade Time
08:29:41
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
2.885 €
(254.42%)
333.48k
UQ1Uniqure NV
15.60 €
(125.63%)
47.61k
XE7CCardiff Oncology Inc
3.64 €
(57.58%)
144.42k
9DRGlimpse Group
1.20 €
(52.87%)
14.47k
C62Chariot Limited
0.03 €
(39.53%)
13.55k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
KEHChinese People Holdings Co Ltd
0.0015 €
(-50.00%)
42.7k
PA8Paion AG
0.0132 €
(-45.90%)
844
1R3Izotropic Corp
0.0222 €
(-30.63%)
1,000
1R6Alset AI Ventures Inc
0.05 €
(-29.08%)
26.8k
AXIAtos SE
0.0023 €
(-14.81%)
717.77M
D7GNel ASA
0.2702 €
(0.11%)
4.06M
PF8European Lithium Limited
0.026 €
(-2.99%)
2.04M
3CPXiaomi Corporation
3.7805 €
(-2.94%)
2M
PLUNPlug Power Inc
2.415 €
(-4.39%)
1.24M

Discussion

View Full Feed
Money hunt Money hunt 4 minutes ago
Round 2 Lets fight
ELAB
BeachBum BeachBum 4 minutes ago
You don’t get it. Everyone wants .01 for there will be many trading ranges on the way up. The problem is lack of volume, people get bored and dump to chase the more liquid shiny object. This stock is a snoozer, always has been. Believe me, I would celebrate if this turtle started moving up. If pumpe
AHRO
govprs govprs 4 minutes ago
I never used those word "load up" gfys
GDVM
MR, MR, 4 minutes ago
Yes year 2040 maybe.
MONI
wickerman wickerman 5 minutes ago
$JL how many bagholders after the offering that's coming?

BWAHAHAHA!
JL
Realdeal3 Realdeal3 5 minutes ago
👍️ I agree
WHEN
mascale mascale 5 minutes ago
Regulation S advantages--(An exemption, not a filing): E.G. Access to a Wider Investor Base: By using the Reg S exemption, companies can tap into the global market and broaden their investor base, potentially increasing liquidity and capital. E.G. Global Branding and Visibility: By reaching int
HIRU
investingnotgambling investingnotgambling 5 minutes ago
Both AZRH and ZHUD just got attacked. Coordinated effort to tank these tickers?

🇺🇸🦅😎
AZRH ZHUD
Gus1212 Gus1212 5 minutes ago
fyi: I just placed a buy order for 10k

Most of the order was filled at the Bid, so all I am saying is you never know which trade is a buy and which trade is a sell.

For those watch each trade execute, it's the 8800 and then the 500
A few more to go.
NWBO
100lbStriper 100lbStriper 5 minutes ago
your 608......... chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553927/download-documents?artifactId=avzPITMWQ_GL0O0SEaRtIBqIN0zDqwendG9UUWyQAlMWsAXTyrQaj4w
NLST
Slightlybetter0 Slightlybetter0 5 minutes ago
There’s a whole lotta back story that investors will probably never know about. Unfortunate what has happened with Movement Industries
MVNT
MR, MR, 5 minutes ago
Thank you for blocking me but only telling you the truth. Look behind the curtain.
MONI
Lone Clone Lone Clone 6 minutes ago
Imperial Metals and Mount Polley Served with Notice of Charges Alleging Violations of the Fisheries Act

https://www.globenewswire.com/news-release/2024/12/10/2994151/0/en/Imperial-Metals-and-Mount-Polley-Served-with-Notice-of-Charges-Alleging-Violations-of-the-Fisheries-Act.html
HGilS HGilS 6 minutes ago
Nasrat mentioned the Eltp team is doing an amazing job with the quota. Nothing more.
ELTP
firebag1 firebag1 6 minutes ago
lmfao especially in the heat like Florida or Belize or Costa Rica!!!! lol
HMBL
LoveThemStocks LoveThemStocks 6 minutes ago
Yeah, time will tell. This is why I said that for right now, I see no reason not to invest in Amprius.
AMPX
Whalatane Whalatane 6 minutes ago
Chromo. re Hyperkalemia / potassium levels . Unlike serum EPA levels , potassium levels can rapidly increase . As an example ...if a CKD dialysis patient stops taking their Valtessa ( for high serum potassium ) for a week ....goes to a party / thanksgiving etc and eats a lot of high potassium food
UNCY
sab63090 sab63090 6 minutes ago
Elon Musk is a powerful and smart guy, glad he is there!
AVXL
IH Admin [Shelly] IH Admin [Shelly] 6 minutes ago
As far as I can tell it's Twitter doing it.
delerious1 delerious1 7 minutes ago
Summing It Up: Hydrogen Swapping System (H2SW)
Addressing Refueling Challenges

Overcomes traditional hydrogen vehicles’ reliance on time-intensive high-pressure refueling stations.
Offers a modular, low-pressure hydrogen cartridge system for quick and seamless swapping.
soma2022 soma2022 7 minutes ago
none. I am surprised by the valuations.
RVNC
m$teamworkotc m$teamworkotc 7 minutes ago
11m 0011 LFG moneybags that have faith still
HMBL
JoJr JoJr 8 minutes ago
So you can't sue them because PROGREDS is not a word...

lol
RDAR
sab63090 sab63090 8 minutes ago
Citrati

Yeah, that resistance goes back a long time with multiple attempts (5 or 6) to break out. No cigar

It's unbelievable that it's just so evident & for so long; I once remember observing something similar in commodity trading years ago with Soybean Oil and when it
AVXL
delerious1 delerious1 8 minutes ago
The Hydrogen Car That Swaps, Stabilizes, and Simplifies – Meet the Virante
December 10, 2024 0 By John Max
Revolutionizing Hydrogen Vehicles with Swappable Hydrogen Cartridges
Hydrogen-powered vehicles have long been recognized as a sustainable alternative to fossil fuel cars. Y

Your Recent History

Delayed Upgrade Clock